For every 10 cancer patients treated, an average of only half will benefit. For some, the treatment won’t have any effect; others may suffer from serious side effects.1 In collaboration with leading pharmaceutical companies, we identify and develop innovative predictive diagnostics to target those patients who are more likely to respond to specific therapies.
We help to advance Personalized Healthcare by delivering diagnostic confidence through a broad menu of high medical value assays. Our standardized, fully-automated and easy-to-use solutions enable rapid turnaround time, empowering physicians to make the right patient decisions more quickly.
Over the last decade, Roche has worked with nearly 200 pharmaceutical and biotechnology companies to develop and commercialize predictive assays that help enable patient access to innovative cancer drugs.
From exploratory research through global patient access, we offer a comprehensive range of solutions to support successful IVD assay development and registration – regardless of drug development stage. Our unrivaled experience and unique expertise in bringing companion diagnostics to market helps partners meet their program timelines and bolster probability of success, while our commercial advantage ensures more patients can benefit from novel therapies, more quickly.
Roche is the world’s #1 provider of companion diagnostics, offering unrivaled experience in developing and commercializing predictive tests that enable personalized treatment strategies for patients.
References
Identifying ALK+ NSCLC patients for targeted treatment
The VENTANA ALK (D5F3) CDx Assay empowers your lab to provide timely results using fully automated, ready-to-use reagents.
